Viridian Therapeutics, Inc. VRDN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $176.35M+51.7% | $212.38M+113% | $169.65M-15.3% | $117.32M+9.0% | $116.22M+26.8% | ||
| $585.84M+12.6% | $662.27M+7.2% | $321.25M-41.9% | $446.03M-3.8% | $520.42M-0.2% | ||
| $22.56M+9.5% | $19.58M-6.2% | $11.01M-21.9% | $15.39M+49.5% | $20.61M+52.3% | ||
| $12.5M— | $20.03M— | —— | —— | —— | ||
| $784.74M+19.4% | $894.23M+21.1% | $571.91M-25.5% | $578.75M-0.5% | $657.24M+4.9% | ||
| $1.13M-2.8% | $1.23M-0.6% | $1.13M-12.8% | $1.09M-27.9% | $1.16M-23.9% | ||
| $2.26M+2,424,731,083% | $2.42M+9.8% | $0.09-100.0% | $0.09-100.0% | $0.09-100.0% | ||
| $888K+81.6% | $1.54M+207% | $1.52M+78.0% | $506K-23.2% | $489K-11.9% | ||
| $789.02M+19.4% | $899.42M+21.1% | $577.14M-25.2% | $582.32M-0.6% | $660.98M+4.9% | ||
| $13.31M+243% | $8.68M+305% | $10.06M+58.8% | $8.52M+171% | $3.89M+45.2% | ||
| $8.36M+64.1% | $19.66M-57.0% | $10.71M+7.0% | $8.19M-9.4% | $5.1M-27.8% | ||
| $274K-4.9% | $367K+27.4% | $372K+29.2% | $288K0.0% | $288K0.0% | ||
| $738K+37.7% | $753K+46.8% | $730K+23.9% | $553K+9.1% | $536K-26.8% | ||
| $385K+150% | $385K+150% | $149K0.0% | $149K0.0% | $154K0.0% | ||
| $51.81M+53.6% | $70.7M+47.7% | $50.7M+22.6% | $52.59M+43.0% | $33.73M+29.1% | ||
| $36.09M+74.5% | $34.24M— | $20.89M+1.8% | $12.35M-29.4% | $20.69M+1.8% | ||
| $2.18M+15.5% | $2.34M+1.4% | $2.58M+19.5% | $2.08M+26.0% | $1.88M+110% | ||
| $12.5M-77.9% | $20.03M-71.7% | $74.17M+15.2% | $67.16M+19.2% | $56.51M+18.1% | ||
| 200M0.0% | 200M+24,591% | 200M0.0% | 200M0.0% | 200M0.0% | ||
| $1.95B+30.0% | $1.93B+30.4% | $1.53B+6.8% | $1.51B+29.1% | $1.5B+29.4% | ||
| -$1.44B-33.3% | -$1.34B-34.4% | -$1.22B-33.0% | -$1.18B-41.0% | -$1.08B-39.8% | ||
| -$558K-328% | $447K+4,570% | $363K-61.1% | $69K+113% | $245K+167% | ||
| $636.01M+5.2% | $722.17M+7.5% | $502.97M-28.9% | $515.17M-2.7% | $604.47M+3.8% | ||
| $789.02M+19.4% | $899.42M+21.1% | $577.14M-25.2% | $582.32M-0.6% | $660.98M+4.9% | ||
| $586.4M-6.6% | $661.82M-7.3% | $481.07M-34.6% | $552.69M-2.2% | $627.85M+2.9% | ||
| $585.84M-6.7% | $662.27M-7.3% | $481.43M-34.6% | $552.76M-2.1% | $628.09M+3.0% | ||
| $585.84M+12.6% | $662.27M+7.2% | $321.25M-41.9% | $446.03M-3.8% | $520.42M-0.2% | ||
| $762.2M+19.7% | —— | $490.9M-34.8% | $563.4M-1.4% | $636.6M+3.8% | ||
| $888K+81.6% | $1.54M+207% | $1.52M+78.0% | $506K-23.2% | $489K-11.9% | ||
| $586.4M-6.6% | $661.82M-7.3% | $481.07M-34.6% | $552.69M-2.2% | $627.85M+2.9% | ||
| $2.26M+7.8% | $2.42M+9.8% | $2.58M+7.6% | $1.98M+8.3% | $2.09M+41.2% | ||
| $2.26M+7.8% | $2.42M+9.8% | $2.58M+7.6% | $1.98M+8.3% | $2.09M+41.2% | ||
| $888K+81.6% | $1.54M+207% | $1.52M+78.0% | $506K-23.2% | $489K-11.9% | ||
| $2.26M+7.8% | $2.42M+9.8% | $2.58M+7.6% | $1.98M+8.3% | $2.09M+41.2% | ||
| $888K+81.6% | $1.54M+207% | $1.52M+78.0% | $506K-23.2% | $489K-11.9% | ||
| $8.36M+64.1% | $19.66M+84.8% | $10.71M+7.0% | $8.19M-9.4% | $5.1M-27.8% | ||
| $38.49M+30.2% | $62.01M+35.6% | $40.63M+17.0% | $35.34M+16.4% | $29.55M+27.6% | ||
| $38.49M+30.2% | $62.01M+35.6% | $40.63M+17.0% | $35.34M+16.4% | $29.55M+27.6% | ||
| $8.36M+64.1% | $19.66M+84.8% | $10.71M+7.0% | $8.19M-9.4% | $5.1M-27.8% | ||
| $12.5M— | $20.03M— | —— | —— | —— | ||
| $5.35M+245% | $3.83M+64.7% | $4.18M+448% | $2.12M+112% | $1.55M+51.1% | ||
| $12.5M— | $20.03M— | —— | —— | —— | ||
| $36.83M+59.4% | $36.96M+1,357% | $23.78M+2.2% | $23.08M+2.1% | $23.11M+5.2% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| 102.5M+25.6% | 101.8M+25.7% | 82.2M+3.8% | 81.7M+27.8% | 81.6M+27.9% | ||
| $1.03M+25.6% | $1.02M+25.7% | $822K+3.8% | $817K+27.9% | $816K+27.9% | ||
| 16.7M+18.6% | —— | 14.5M+27.8% | 13.9M+26.5% | 14.1M+36.9% | ||
| $139.5M+22.6% | —— | $103.3M+18.6% | $106.3M+14.7% | $113.8M+23.3% | ||
| 6.7M+197% | —— | 10.5M+126% | 10.7M+150% | 2.3M+6.8% | ||
| $52K-90.1% | $495K-11.1% | $390K-62.3% | $276K+820% | $523K+481% | ||
| $612K+120% | $48K-91.5% | $27K-73.5% | $206K-64.0% | $278K-39.2% | ||
| $12.5M— | $20.03M— | —— | —— | —— | ||
| $200K— | $10M— | —— | —— | —— | ||
| $5.92M— | $8.6M-25.8% | $10.84M— | —— | —— | ||
| $16.69M— | $15.99M-17.5% | $11.82M— | —— | —— | ||
| $5.35M+245% | $3.83M+64.7% | $4.18M+448% | $2.12M+112% | $1.55M+51.1% | ||
| $612K+120% | $48K-91.5% | $27K-73.5% | $206K-64.0% | $278K-39.2% | ||
| $52K-90.1% | $495K-11.1% | $390K-62.3% | $276K+820% | $523K+481% | ||
| $586.4M-6.6% | $661.82M-7.3% | $481.07M-34.6% | $552.69M-2.2% | $627.85M+2.9% | ||
| $585.84M-6.7% | $662.27M-7.3% | $481.43M-34.6% | $552.76M-2.1% | $628.09M+3.0% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $200M0.0% | $200M0.0% | $200M0.0% | $200M0.0% | $200M0.0% | ||
| $102.46M+25.6% | $101.83M+25.7% | $82.23M+3.8% | $81.65M+27.8% | $81.59M+27.9% | ||
| $102.46M+25.6% | $101.83M+25.7% | $82.23M+3.8% | $81.65M+27.8% | $81.59M+27.9% | ||
| $12.5M— | $20.03M— | —— | —— | —— | ||
| $12.5M— | $20.03M— | —— | —— | —— | ||
| $139.5M+22.6% | —— | $103.3M+18.6% | $106.3M+14.7% | $113.8M+23.3% | ||
| $568K+8.6% | $2.44M+184% | $1.84M+204% | $688K+16.6% | $523K+6.7% | ||
| $16.75M+18.6% | —— | $14.5M+27.8% | $13.9M+26.5% | $14.12M+36.9% | ||
| $6.7M+197% | —— | $10.5M+126% | $10.74M+150% | $2.26M+6.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viridian Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 15.15 — current assets exceed current liabilities.
- Where does Viridian Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.